For research use only
| Cat No. | ABC-TC0503 |
| Product Type | Human Bone Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone |
| Product Code | KHOS240S; 240S |
The growth properties of KHOS-240S are similar to HOS. The KHOS-240S does not represent a rescuable Kirsten murine sarcoma virus genome.
KHOS‑240S is a human osteosarcoma tumor cell line derived from bone tissue of a 13‑year‑old Caucasian female patient with primary bone sarcoma. It was established as a revertant subclone of the KHOS/NP line after heat-shock and subcloning and is a virus-negative subclone derived from KHOS/NP, with growth properties similar to the HOS parent line. The cells exhibit adherent, epithelial‑like (fibroblast‑like) morphology and form monolayers in vitro, with an aneuploid karyotype consistent with osteosarcoma cell biology. KHOS‑240S lacks a rescuable Kirsten murine sarcoma virus genome and is not tumorigenic in immunosuppressed mice, although it can form colonies in semisolid media, reflecting its transformed phenotype without overt in vivo tumor formation under certain conditions. Genetic background information and expression features reported for this line are based on published literature and database records. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV‑1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | KHOS240S; 240S |
| Species | Human |
| Cat.No | ABC-TC0503 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bone Cancer Cell Lines |
KHOS‑240S is used as an in vitro human osteosarcoma model for studies of bone tumor cell proliferation, signal transduction pathways associated with sarcoma biology, and mechanisms underlying therapeutic resistance. It supports investigation of chemotherapeutic compound effects, kinase signaling and drug sensitivity profiles, and comparative analyses with other osteosarcoma lines to explore malignant cell behavior and molecular mechanisms relevant to bone cancer research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
